查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2048218

多癌種早期檢測市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、最終用戶、地區和競爭對手分類，2021-2031年

Multi Cancer Early Detection Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End-user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球多癌症早期檢測 (MCED) 市場預計將從 2025 年的 10.6114 億美元大幅成長至 2031 年的 17.9833 億美元，複合年成長率為 9.19%。

MCED技術利用液態生物檢體，只需一份血液樣本即可識別多種癌症類型，並分析循環腫瘤DNA和甲基化模式等生物標記。全球癌症發生率的上升是推動該市場成長的主要因素，也因此迫切需要高效、非侵入性的篩檢工具，以期透過早期診斷降低死亡率。此外，MCED能夠檢測目前尚無標準篩檢方案的惡性腫瘤，例如胰臟癌和卵巢癌，這加速了其在預防醫學領域的應用。美國癌症協會預測，到2025年，美國將新增約2,041,910例癌症病例，凸顯了擴充性檢測方法的迫切性。然而，市場擴張的主要障礙在於缺乏足夠的臨床效用數據來證明其能夠實際降低整體死亡率。這使得監管核准和製定廣泛的保險報銷政策變得複雜，最終導致患者難以獲得該技術。

市場概覽
預測期 2027-2031
市場規模：2025年 1,061,140,​​000 美元
市場規模：2031年 1,798,330,000 美元
複合年成長率：2026-2031年 9.19%
成長最快的細分市場 液態生物檢體
最大的市場 歐洲

市場促進因素

投資和創投的顯著創業投資正強勁推動全球多癌症種早期檢測市場的發展，加速尖端診斷平台的商業化進程，並促進廣泛的臨床檢驗。資金的湧入使企業能夠應對複雜的監管流程，拓展業務範圍，確保突破性的篩檢方案能夠更快地惠及病患。例如，Freenome公司於2025年12月宣布計劃資金籌措約3.3億美元，用於支持其基於血液的多篩檢篩檢測試的商業化。這凸顯了此類資金注入對於資助耗資巨大的多年縱向研究至關重要，這些研究對於確立臨床效用和獲得保險報銷至關重要，從而直接加速產品上市。同時，液態生物檢體和次世代定序技術的不斷進步顯著提高了檢測的靈敏度和特異性，有效解決了早期惡性腫瘤檢測的技術難題。這些技術進步降低了假陽性率，並將可檢測的癌症類型擴展到傳統檢測組合之外，尤其是在難以檢測的癌症類型方面。例如，2025年7月，美因茨生物醫學公司（Mainz Biomed）報告稱，其專有的胰腺癌檢測生物標記在可行性研究中達到了95%的靈敏度和98%的特異性。這些技術日益增強的臨床可靠性體現在其強勁的市場表現上，也推動了它們的普及應用。 Exact Sciences公司累計，篩檢業務在2025年第三季的收入為6.66億美元，這表明擴充性的早期檢測調查方法正被越來越廣泛地採用。

市場挑戰

全球多癌種早期檢測（MCED）市場擴張的主要障礙在於缺乏確切的臨床效用數據，無法證明其能切實降低死亡率。儘管現有技術可以識別癌症徵兆，但監管機構和保險公司要求提供嚴謹的縱向證據，證明MCED早期檢測能夠提高生存率；否則，MCED無法獲得廣泛核准和保險覆蓋。這種關鍵證據的匱乏迫使製造商依賴直接面對消費者的模式和有限的試驗計畫，導致其市場滲透率顯著受限，僅限於能夠承擔高昂自付費用的少數人群。因此，缺乏標準化的報銷政策造成了經濟壁壘，將大量患者拒之門外，阻礙了MCED從專業創新技術轉變為標準的預防性護理。檢驗這些臨床益處所需的大量研究凸顯了這項挑戰的嚴峻性。根據美國國家癌症研究所2025年報告，癌症篩檢研究網路正準備啟動「先鋒研究」（Vanguard Study），該研究計劃招募多達24,000名參與者，以評估多癌種檢測在臨床環境中的實際應用價值。這項舉措表明，該行業仍處於收集大量必要數據以證明其有效性的階段。在完成此類綜合研究並滿足降低死亡率的監管要求之前，市場將繼續受到保險覆蓋範圍有限和商業性擴充性受限的限制。

市場趨勢

將人工智慧 (AI) 應用於生物標記發現正在改變市場格局，它能夠識別傳統方法常常忽略的新型癌症特徵。與主要提高檢測靈敏度的標準液態生物檢體技術不同，這一趨勢利用機器學習來解讀複雜的多體學數據，從而加速新診斷目標的開發。例如，2025 年 4 月，Google雲端作為癌症人工智慧聯盟 (Cancer AI Alliance) 的成員，與 Ai2 合作，向一個研究機構聯盟承諾提供總計 2000 萬美元的資金，用於建立分析大規模癌症數據的 AI 基礎設施。這項技術變革將使企業能夠識別超越簡單基因組變異的複雜模式，從而顯著縮短可擴展調查方法的發現階段。同時，企業贊助的癌症篩檢計畫的興起正在迅速擴大多癌早期檢測 (MCED) 的商業性應用範圍，使其超越傳統的臨床環境。企業正擴大將這些診斷工具納入員工福利計劃，旨在降低治療晚期癌症的高昂成本，並改善員工的整體健康。這種推廣管道已被證明在市場滲透方面極為有效，顯著提高了產品的使用率，且無需依賴傳統的保險公司報銷。例如，GRAIL在2025年2月報告稱，2024年全年Galleri檢測的銷量超過13.7萬份。這個銷售數字主要得益於產品的普及，尤其是透過雇主和人壽保險管道。這一趨勢標誌著一個關鍵的轉折點，私營部門在預防性篩檢策略的廣泛實施中發揮主導促進者。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：多種癌症早期檢測的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（液態生物檢體、基因檢測、實驗室自建檢測、其他）
    • 依最終用戶（醫院、診斷檢驗實驗室等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美多種癌症早期檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲多種癌症早期檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區多種癌症早期檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲多種癌症早期檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲多種癌症早期檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球多癌症種早期檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Grail, LLC
  • Exact Sciences Corporation.
  • Foundation Medicine, Inc.
  • AnchorDx Medical Co Ltd
  • Guardant Health, Inc.
  • Burning Rock Biotech Limited
  • genecast biotechnology co. ltd
  • Laboratory for Advanced Medicine, Inc.
  • Singlera Genomics Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17568

The Global Multi Cancer Early Detection (MCED) Market is projected to expand significantly, growing from USD 1061.14 Million in 2025 to USD 1798.33 Million by 2031, reflecting a 9.19% Compound Annual Growth Rate. MCED technology leverages liquid biopsies to identify various cancer types from a single blood sample, analyzing biomarkers such as circulating tumor DNA or methylation patterns. This market growth is primarily driven by the increasing global incidence of cancer, which creates a critical demand for effective, non-invasive screening tools designed to lower mortality rates through earlier diagnosis. Furthermore, MCED's capacity to detect malignancies currently lacking standard screening protocols, such as pancreatic and ovarian cancers, is accelerating its adoption into preventative healthcare frameworks. According to the American Cancer Society, an estimated 2,041,910 new cancer cases are expected in the United States in 2025, emphasizing the urgent need for scalable detection methods. However, a key hurdle impeding market expansion is the insufficient clinical utility data demonstrating that these tests definitively reduce overall mortality, complicating regulatory approvals and the establishment of widespread reimbursement policies, thereby limiting patient accessibility.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1061.14 Million
Market Size 2031USD 1798.33 Million
CAGR 2026-20319.19%
Fastest Growing SegmentLiquid Biopsy
Largest MarketEurope

Market Driver

A substantial surge in investment and venture capital is vigorously advancing the Global Multi Cancer Early Detection Market, facilitating the rapid commercialization and extensive clinical validation of cutting-edge diagnostic platforms. This financial inflow enables companies to navigate intricate regulatory processes and broaden their operational scope, ensuring that groundbreaking screening solutions become available to patients more quickly. For example, Freenome announced in December 2025 its intention to raise approximately $330 million to support the commercial launch of its blood-based multi-cancer screening tests, underscoring how crucial such capital injections are for funding the costly, multi-year longitudinal studies required to establish clinical utility and secure reimbursement, thereby directly accelerating market availability. Concurrently, ongoing advancements in liquid biopsy and next-generation sequencing technologies are significantly improving the sensitivity and specificity of assays, effectively addressing the technical complexities involved in detecting early-stage malignancies. These technological enhancements are reducing false positive rates and broadening the spectrum of detectable cancers beyond conventional panels, especially for hard-to-detect types. Mainz Biomed, for instance, reported in July 2025 that its proprietary biomarkers for pancreatic cancer detection achieved 95% sensitivity and 98% specificity in feasibility studies. The increasing clinical reliability of these technologies is fostering widespread adoption, as evidenced by robust market performance; Exact Sciences generated $666 million in screening revenue during the third quarter of 2025, highlighting the growing uptake of scalable early detection methodologies.

Market Challenge

The primary obstacle hindering the expansion of the Global Multi Cancer Early Detection (MCED) Market is the lack of conclusive clinical utility data proving a definite reduction in mortality rates. While existing technologies are capable of identifying cancer signals, regulatory bodies and payers mandate rigorous longitudinal evidence demonstrating that early detection via MCED leads to improved survival outcomes before granting extensive approval or reimbursement coverage. This critical evidence gap compels manufacturers to rely on direct-to-consumer sales models or limited pilot programs, which significantly restricts market penetration to a segment of the population able to bear high out-of-pocket expenses. Consequently, the absence of standardized reimbursement policies creates a financial barrier that isolates the vast majority of patients, thereby impeding the transition of MCEDs from specialized innovations to standard preventative care. The extensive research required to validate these clinical benefits highlights the profound nature of this challenge. As reported by the National Cancer Institute in 2025, the Cancer Screening Research Network was preparing to launch the 'Vanguard Study,' aiming to enroll up to 24,000 participants to assess the practicality of multi-cancer detection assays in clinical settings. This initiative illustrates that the industry is still in the early stages of gathering the extensive data necessary to prove efficacy. Until such comprehensive studies are completed and fulfill regulatory requirements for mortality reduction, the market will remain constrained by limited payer coverage and restricted commercial scalability.

Market Trends

The integration of Artificial Intelligence (AI) for biomarker discovery is transforming the market by enabling the identification of novel cancer signatures that traditional methods often miss. Unlike standard liquid biopsy advancements, which primarily enhance assay sensitivity, this trend leverages machine learning to decipher intricate multi-omics data, thereby accelerating the development of new diagnostic targets. For example, Google Cloud, in April 2025, committed a combined $20 million with Ai2 to a consortium of research institutions to build AI infrastructures specifically for analyzing large-scale cancer data as part of the Cancer AI Alliance. This technological shift allows companies to move beyond simple genomic alterations and identify complex patterns, significantly shortening the discovery phase for scalable detection methodologies. Simultaneously, the emergence of employer-sponsored cancer screening programs is rapidly expanding the commercial reach of multi-cancer early detection (MCED) tests beyond traditional clinical environments. Corporations are increasingly incorporating these diagnostic tools into employee benefit packages, aiming to mitigate the substantial costs associated with treating late-stage diseases and to enhance overall workforce wellness. This adoption channel is proving highly effective for market penetration, driving significant utilization volumes independently of conventional payer reimbursement. GRAIL, for instance, reported in February 2025 that it sold over 137,000 Galleri tests throughout 2024, a volume substantially driven by uptake across employer and life insurance channels. This trend signifies a pivotal shift where the private sector is acting as a primary catalyst for the widespread implementation of preventative screening strategies.

Key Market Players

  • Grail, LLC
  • Exact Sciences Corporation.
  • Foundation Medicine, Inc.
  • AnchorDx Medical Co Ltd
  • Guardant Health, Inc.
  • Burning Rock Biotech Limited
  • genecast biotechnology co. ltd
  • Laboratory for Advanced Medicine, Inc.
  • Singlera Genomics Inc.

Report Scope

In this report, the Global Multi Cancer Early Detection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Multi Cancer Early Detection Market, By Type

  • Liquid Biopsy
  • Gene Panel
  • LDT
  • Others

Multi Cancer Early Detection Market, By End-user

  • Hospitals
  • Diagnostic Laboratories
  • Others

Multi Cancer Early Detection Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Multi Cancer Early Detection Market.

Available Customizations:

Global Multi Cancer Early Detection Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Multi Cancer Early Detection Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Liquid Biopsy, Gene Panel, LDT & Others)
    • 5.2.2. By End-user (Hospitals, Diagnostic Laboratories, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Multi Cancer Early Detection Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End-user
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Multi Cancer Early Detection Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End-user
    • 6.3.2. Canada Multi Cancer Early Detection Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End-user
    • 6.3.3. Mexico Multi Cancer Early Detection Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End-user

7. Europe Multi Cancer Early Detection Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End-user
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Multi Cancer Early Detection Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End-user
    • 7.3.2. France Multi Cancer Early Detection Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End-user
    • 7.3.3. United Kingdom Multi Cancer Early Detection Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End-user
    • 7.3.4. Italy Multi Cancer Early Detection Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End-user
    • 7.3.5. Spain Multi Cancer Early Detection Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End-user

8. Asia Pacific Multi Cancer Early Detection Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End-user
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Multi Cancer Early Detection Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End-user
    • 8.3.2. India Multi Cancer Early Detection Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End-user
    • 8.3.3. Japan Multi Cancer Early Detection Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End-user
    • 8.3.4. South Korea Multi Cancer Early Detection Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End-user
    • 8.3.5. Australia Multi Cancer Early Detection Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End-user

9. Middle East & Africa Multi Cancer Early Detection Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End-user
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Multi Cancer Early Detection Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End-user
    • 9.3.2. UAE Multi Cancer Early Detection Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End-user
    • 9.3.3. South Africa Multi Cancer Early Detection Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End-user

10. South America Multi Cancer Early Detection Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End-user
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Multi Cancer Early Detection Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End-user
    • 10.3.2. Colombia Multi Cancer Early Detection Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End-user
    • 10.3.3. Argentina Multi Cancer Early Detection Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End-user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Multi Cancer Early Detection Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Grail, LLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Exact Sciences Corporation.
  • 15.3. Foundation Medicine, Inc.
  • 15.4. AnchorDx Medical Co Ltd
  • 15.5. Guardant Health, Inc.
  • 15.6. Burning Rock Biotech Limited
  • 15.7. genecast biotechnology co. ltd
  • 15.8. Laboratory for Advanced Medicine, Inc.
  • 15.9. Singlera Genomics Inc.

16. Strategic Recommendations

17. About Us & Disclaimer